To evaluate ATP7A’s role in glioma stemness in vivo, intracranial limiting dilution assays (10,000–100 cells) showed that ATP7A knockdown extended survival, indicating reduced tumor initiation (Supplemental Figure 10B). The gene discussed is ATP7A; the disease is central nervous system cancer.